Early Fluid Resolution Predicts Faricimab Durability

Post hoc analysis suggests rapid retinal fluid clearance may help identify nAMD patients who can maintain longer faricimab dosing intervals

Share

1

Early resolution of retinal fluid may predict treatment intervals for nAMD.
2

TENAYA and LUCERNE were phase 3 trials comparing faricimab and aflibercept.
3

Resolution of intraretinal and subretinal fluid linked to longer dosing intervals.
4

Faricimab acts on both Ang-2 and VEGF-A.
5

Higher odds of extended dosing intervals for those with early fluid resolution.
6

Similar visual outcomes for patients with early resolution.
7

Potential to reduce treatment burdens on healthcare systems.